13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03355365
(ClinicalTrials.gov)
September 21, 201814/11/2017Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple SclerosisAutologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered IntrathecallyMultiple SclerosisBiological: Intrathecal MSC-NP injection;Other: Intrathecal saline injectionTisch Multiple Sclerosis Research Center of New YorkNULLActive, not recruiting18 Years65 YearsAll50Phase 2United States
2NCT02228213
(ClinicalTrials.gov)
October 201421/8/2014Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple SclerosisA Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisBiological: MIS416;Drug: SalineInnate ImmunotherapeuticsINC ResearchCompleted18 Years70 YearsAll93Phase 2Australia;New Zealand
3NCT01911377
(ClinicalTrials.gov)
October 201325/7/2013Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MSThe Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple SclerosisNeuropathic Pain;AllodyniaDrug: Botulinum Toxin Type A;Drug: Normal Saline for InjectionUniversity of ManitobaAllerganTerminated18 Years70 YearsBoth12Phase 2Canada
4NCT01600716
(ClinicalTrials.gov)
June 13, 201215/5/2012Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)Urinary Incontinence;Multiple Sclerosis;Neurogenic BladderBiological: OnabotulinumtoxinA;Drug: Placebo (Normal Saline)AllerganNULLCompleted18 YearsN/AAll144Phase 3United States;Belgium;Canada;Czechia;France;Poland;Portugal;Russian Federation;Czech Republic
5NCT01435993
(ClinicalTrials.gov)
September 8, 201125/8/2011Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple SclerosisA Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.Multiple Sclerosis, Relapsing-RemittingDrug: GSK1223249;Other: Saline placeboGlaxoSmithKlineNULLTerminated18 Years60 YearsAll3Phase 1Italy;Norway;Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01212094
(ClinicalTrials.gov)
September 201029/9/2010Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)Multiple SclerosisDrug: Rituximab;Other: normal salineNational Institute of Neurological Disorders and Stroke (NINDS)NULLTerminated18 Years65 YearsAll44Phase 1;Phase 2United States
7NCT00986960
(ClinicalTrials.gov)
December 200929/9/2009Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up StudyMultiple SclerosisDrug: repository corticotropin injection;Drug: SalineUniversity at BuffaloNULLTerminated18 Years65 YearsAll3Phase 2United States
8NCT01091727
(ClinicalTrials.gov)
October 200622/3/2010Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor OveractivityProspective Randomized Double-blind Trial of Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Spinal Cord Injury or Multiple SclerosisNeurogenic Detrusor OveractivityDrug: Botulinum toxin ASunnybrook Health Sciences Centreethica Clinical Research Inc.Completed18 Years75 YearsBoth57Phase 3Canada